Prostate and Bladder Cancer US Policy Strategy
The Challenge
The client acquired a new therapeutic area to expand its oncology portfolio in Bladder cancer, complementing it existing drugs in Prostate cancer. The client sought to understand and shape the US policy environment focusing on prostate and bladder cancer at the national and local levels. The client also needed to alignment between both GU teams on the unique and shared patient unmet needs, policy priorities, gaps and key influencers in order to develop a policy strategic plan.
Our Solution
US Policy Landscape Assessment and Cross-functional Strategic Plan:
Conducted in-depth research and analysis of current prostate and bladder cancer resources, national and state policies, key opinion leaders, professional societies, and patient advocacy group activities.
Reviewed internal cross-functional plans, communication materials, and transition plans to ensure alignment across GU teams.
Held internal interviews with Policy, Advocacy, Medical Affairs, Market Access, and Commercial teams to capture both external needs and internal priorities.
Developed a GU cancer policy strategy and tactical plan with timelines, cross-functional activities, and initiatives to advance health equity, align healthcare professional (HCP) communications, and encourage shared decision-making.
Designed a framework mapping prioritized U.S. legislation relevant to prostate and bladder cancer, with recommended actions and key stakeholder targets.
Benefit to Client
Strategic Roadmap for Action: Received a comprehensive, actionable strategy document serving as a foundational guide for prostate and bladder cancer teams.
Team Alignment for Unified Advocacy: Achieved alignment between GU teams on unmet needs, shared policy priorities, and external engagement strategies.
Consistency in Communications: Established consistent key talking points across departments and identified initiatives to advance into 2025 and beyond.
Precision in Targeting Health Equity: Gained clarity on targeted activities—including owners, stakeholders, and timing—to address disparities and improve health equity in GU cancer care.
DKI DIFFERENCE
Aligned the company’s broader strategic imperatives with specific policy team goals, ensuring the tactical plan drove impact across the organization.
Created a visually compelling framework to connect policy priorities and legislation directly to patient benefit in prostate and bladder cancer.
Identified high-priority policymakers, state and local influencers, advocacy leaders, and cross-functional champions to accelerate policy progress and strengthen health equity outcomes.
